Cargando…

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD

Detalles Bibliográficos
Autores principales:	Messchendorp, A. Lianne, Kramers, Bart J., Spithoven, Edwin M., Stade, Katrin, Meijer, Esther, Gansevoort, Ron T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698293/ https://www.ncbi.nlm.nih.gov/pubmed/31440707 http://dx.doi.org/10.1016/j.ekir.2019.04.027

Ejemplares similares

Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
por: Messchendorp, A Lianne, et al.
Publicado: (2019)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
por: Messchendorp, A. Lianne, et al.
Publicado: (2018)

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment
por: Zittema, Debbie, et al.
Publicado: (2017)

Acid-Base Homeostasis During Vasopressin V2 Receptor Antagonist Treatment in Autosomal Dominant Polycystic Kidney Disease Patients
por: Heida, Judith E., et al.
Publicado: (2021)

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression
por: Messchendorp, A. Lianne, et al.
Publicado: (2017)

Vaccinated kidney transplant recipients are yet not sufficiently protected against COVID-19
por: Messchendorp, A Lianne, et al.
Publicado: (2023)

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study
por: Lantinga, Marten A., et al.
Publicado: (2016)

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan
por: Kramers, Bart J., et al.
Publicado: (2018)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

The imaging of total kidney volume in ADPKD
por: Cavoli, Gioacchino Li, et al.
Publicado: (2020)

Simultaneous laparoscopic nephrectomy in ADPKD
por: Baishya, Ramen Kumar, et al.
Publicado: (2010)

The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels
por: Ettema, Esmée M., et al.
Publicado: (2017)

Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study
por: Winterbottom, Jean, et al.
Publicado: (2022)

Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
por: Kramers, Bart J, et al.
Publicado: (2020)

Imaging Biomarkers in Young Patients With ADPKD
por: Yang, Xinyi, et al.
Publicado: (2023)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

The association of urinary epidermal growth factors with ADPKD disease severity and progression
por: Harskamp, Laura R, et al.
Publicado: (2023)

The effect of vasopressin and hydrocortisone on cytokine trajectories
por: Cleasby, Charlotte, et al.
Publicado: (2023)

Screening and Management for Intracranial Aneurysms in Japanese Patients With ADPKD
por: Matsuura, Ryo, et al.
Publicado: (2022)

Somatostatin Analogues for Receptor Targeted Photodynamic Therapy
por: Kaščáková, Slávka, et al.
Publicado: (2014)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
por: Liu, Wenjuan, et al.
Publicado: (2017)

SUN-323 Somatostatin Analogue: An Effective Treatment for Pseudoglucagonoma Syndrome
por: Vallejo Garcia, Franco, et al.
Publicado: (2019)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

Vasopressin and its analogues in shock states: a review
por: Demiselle, Julien, et al.
Publicado: (2020)

The Time-Dependent Association of Torque Teno Virus Load with the Level of SARS-CoV-2 S1 IgG Antibodies Following COVID-19 Vaccination in Kidney Transplant Recipients
por: Imhof, Céline, et al.
Publicado: (2023)

Vasopressin Is No Inotrope
por: Roeleveld, Peter Paul
Publicado: (2018)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

The potential role of somatostatin analogues in breast cancer treatment.
por: Pollak, M.
Publicado: (1997)

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue
por: Herlin, Gunnar, et al.
Publicado: (2011)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy
por: Collins, Michael, et al.
Publicado: (2018)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Somatostatin analogues labeled with copper radioisotopes: current status
por: Marciniak, Aleksandra, et al.
Publicado: (2017)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3ka7qsa99kqaed65rguev37a8